BlockBeats News, May 6th, Anti-aging company NewLimit, founded by Coinbase CEO Brian Armstrong, announced the completion of a $130 million Series B funding round. This round of funding was led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, and Khosla Ventures, among others.
NewLimit aims to extend people's healthy lifespan through genetic programming of cells. Founded four years ago by Brian Armstrong, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, the company claims to have made significant progress in developing a therapeutic approach to rejuvenate aging cells.
The company has identified three prototype drugs that can reprogram liver cells. Bryers stated that laboratory experiments at NewLimit have shown that this regeneration therapy can restore the cells' ability to process fat and alcohol. The company measures its progress by comparing how cells from young and old individuals respond to these substances. Liver cells processed through NewLeaf epigenetic reprogramming behave more like young cells.
Despite promising early results, NewLimit is still several years away from starting human trials.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。